Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a €92.00 ($106.98) target price by stock analysts at UBS Group in a report issued on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 46.17% from the stock’s current price.

A number of other equities analysts also recently commented on FME. Berenberg Bank reiterated a “buy” rating on shares of United Parcel Service in a research note on Friday. Deutsche Bank restated a “buy” rating on shares of Continental in a research note on Wednesday, July 24th. Kepler Capital Markets set a €80.00 ($93.02) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Thursday, May 2nd. Jefferies Financial Group restated a “buy” rating and issued a GBX 99 ($1.29) target price on shares of in a research note on Friday, June 28th. Finally, Barclays set a €81.00 ($94.19) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Buy” and an average price target of €82.57 ($96.01).

ETR:FME opened at €62.94 ($73.19) on Tuesday. The firm has a market capitalization of $20.58 billion and a P/E ratio of 9.80. Fresenius Medical Care AG & Co. KGaA has a one year low of €55.44 ($64.47) and a one year high of €91.74 ($106.67). The stock has a 50-day moving average price of €68.71. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 100.05.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Does a trade war provide a risk to the global economy?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.